Search research articles
Contact Us
Filters
Showing results (11-20 of 14) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 14 results.
The EMBO Journal
|
December 6, 2011
Structural insights into the neutralization mechanism of a higher primate antibody against dengue virus
Joseph J B Cockburn, M Erika Navarro Sanchez, Ana P Goncalvez, et al.
Virology
|
October 17, 2009
Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype
W W Shanaka I Rodrigo, Olivia K T Block, Christopher Lane, et al.
Scientific Reports
|
September 6, 2018
Chimeric yellow fever 17D-Zika virus (ChimeriVax-Zika) as a live-attenuated Zika virus vaccine
Maryann Giel-Moloney, Ana P Goncalvez, John Catalan, et al.
Vaccine
|
March 19, 2025
A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of age
Theresa E Hegmann, Emmanuel B Walter, Michael J Smith, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 14) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 14 results.
The EMBO Journal
|
December 6, 2011
Structural insights into the neutralization mechanism of a higher primate antibody against dengue virus
Joseph J B Cockburn, M Erika Navarro Sanchez, Ana P Goncalvez, et al.
Virology
|
October 17, 2009
Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype
W W Shanaka I Rodrigo, Olivia K T Block, Christopher Lane, et al.
Scientific Reports
|
September 6, 2018
Chimeric yellow fever 17D-Zika virus (ChimeriVax-Zika) as a live-attenuated Zika virus vaccine
Maryann Giel-Moloney, Ana P Goncalvez, John Catalan, et al.
Vaccine
|
March 19, 2025
A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of age
Theresa E Hegmann, Emmanuel B Walter, Michael J Smith, et al.
Page
of 2